JP5600329B2 - イミノ糖およびウイルス性疾患を治療する方法 - Google Patents

イミノ糖およびウイルス性疾患を治療する方法 Download PDF

Info

Publication number
JP5600329B2
JP5600329B2 JP2011551274A JP2011551274A JP5600329B2 JP 5600329 B2 JP5600329 B2 JP 5600329B2 JP 2011551274 A JP2011551274 A JP 2011551274A JP 2011551274 A JP2011551274 A JP 2011551274A JP 5600329 B2 JP5600329 B2 JP 5600329B2
Authority
JP
Japan
Prior art keywords
dnj
substituted
dengue
unsubstituted
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011551274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518649A5 (enExample
JP2012518649A (ja
Inventor
ラムステッド，アーバン
クローゼ，ブレナン
ジットズマン，ニコル
ドゥウェック，レイモンド，エイ．
バターズ，テリー，デイ．
Original Assignee
ユナイテッド セラピューティクス コーポレーション
ユニバーシティ・オブ・オックスフォード
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド セラピューティクス コーポレーション, ユニバーシティ・オブ・オックスフォード filed Critical ユナイテッド セラピューティクス コーポレーション
Publication of JP2012518649A publication Critical patent/JP2012518649A/ja
Publication of JP2012518649A5 publication Critical patent/JP2012518649A5/ja
Application granted granted Critical
Publication of JP5600329B2 publication Critical patent/JP5600329B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2011551274A 2009-02-23 2010-02-22 イミノ糖およびウイルス性疾患を治療する方法 Expired - Fee Related JP5600329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20236709P 2009-02-23 2009-02-23
US61/202,367 2009-02-23
US27225509P 2009-09-04 2009-09-04
US61/272,255 2009-09-04
PCT/US2010/024920 WO2010096764A1 (en) 2009-02-23 2010-02-22 Iminosugars and methods of treating viral diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014165290A Division JP5940607B2 (ja) 2009-02-23 2014-08-14 イミノ糖およびウイルス性疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2012518649A JP2012518649A (ja) 2012-08-16
JP2012518649A5 JP2012518649A5 (enExample) 2014-04-17
JP5600329B2 true JP5600329B2 (ja) 2014-10-01

Family

ID=42634239

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011551274A Expired - Fee Related JP5600329B2 (ja) 2009-02-23 2010-02-22 イミノ糖およびウイルス性疾患を治療する方法
JP2014165290A Expired - Fee Related JP5940607B2 (ja) 2009-02-23 2014-08-14 イミノ糖およびウイルス性疾患を治療する方法
JP2016099696A Pending JP2016175937A (ja) 2009-02-23 2016-05-18 イミノ糖およびウイルス性疾患を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014165290A Expired - Fee Related JP5940607B2 (ja) 2009-02-23 2014-08-14 イミノ糖およびウイルス性疾患を治療する方法
JP2016099696A Pending JP2016175937A (ja) 2009-02-23 2016-05-18 イミノ糖およびウイルス性疾患を治療する方法

Country Status (8)

Country Link
US (4) US8450345B2 (enExample)
EP (1) EP2398321B1 (enExample)
JP (3) JP5600329B2 (enExample)
KR (2) KR20120042716A (enExample)
CN (2) CN106420740A (enExample)
CA (1) CA2753195C (enExample)
ES (1) ES2579628T3 (enExample)
WO (1) WO2010096764A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
WO2014143999A1 (en) * 2013-03-15 2014-09-18 Unither Virology, Llc Antibacterial compounds
CA2924026C (en) * 2013-09-16 2021-12-28 Emergent Virology Llc Deoxynojirimycin derivatives and methods of their using
CA2966893C (en) 2014-11-05 2023-10-24 Emergent Virology Llc Iminosugars
US20190282558A1 (en) * 2016-05-16 2019-09-19 Emergent Virology Llc Methods of Treating Zika Virus Infection
KR101942757B1 (ko) 2017-08-23 2019-01-28 주식회사 유앤아이미트 마이크로웨이브를 이용한 n-노닐데옥시노지리마이신의 제조방법
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途
CN119841765B (zh) * 2025-01-09 2025-10-10 中南大学 Dnj衍生物、药物组合物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2839309A1 (de) 1978-09-09 1980-03-27 Bayer Ag 3,4,5-trihydroxypiperidin-derivate
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US4994572A (en) 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5200523A (en) 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
US5206251A (en) 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
AU761748B2 (en) * 1997-12-11 2003-06-12 Chancellor, Masters And Scholars Of The University Of Oxford, The Inhibition of membrane-associated viral replication
EA004705B1 (ru) 1998-02-12 2004-06-24 Дж.Д.Серл Энд Ко. Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
EP1714676A3 (en) 1998-02-12 2006-11-15 G.D. Searle LLC. Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9828474D0 (en) 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
ES2311921T3 (es) 1999-02-12 2009-02-16 United Therapeutics Corporation N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
EP1556036A2 (en) * 2002-09-23 2005-07-27 The Chancellor, Masters And Scholars Of The University Of Oxford Use of iminosugar derivatives to inhibit ion channel activity
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050256168A1 (en) 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
GB0501352D0 (en) 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
WO2006096769A2 (en) * 2005-03-08 2006-09-14 Intermune, Inc. Use of alpha-glucosidase inhibitors to treat alphavirus infections
CA2601797A1 (en) 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
BRPI0615974A2 (pt) 2005-07-27 2011-05-31 University Of Florida Research Foundation, Inc., uso de choque térmico para tratar uma doença ocular em um indivìduo, método para recrutar uma célula-tronco para um tecido ocular de um indivìduo com necessidade da mesma, uso de choque térmico para tratar uma doença ou um distúrbio ocular em um indivìduo com necessidade do mesmo, uso de choque térmico para regenerar a retina em um indivìduo com necessidade do mesmo, uso de choque térmico para reparar os danos ao epitélio pgmentar da retina em um indivìduo com necessidade do mesmo, uso de choque térmico para tratar a degeneração macular em um indivìduo com necessidade do mesmo, composição farmacêutica para o recrutamento de células-tronco, composição farmacêutica para recrutamento de células-tronco em um tecido ocular, kit e método para identificar um agente que aumenta o recrutamento de células-tronco em um tecido ocular
US20070244184A1 (en) 2006-01-09 2007-10-18 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
DE602007008870D1 (de) 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
CN101489554A (zh) * 2006-05-24 2009-07-22 联合治疗公司 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
CN102727437A (zh) 2006-08-02 2012-10-17 牛津大学院长校长专家委员会 病毒感染的脂质体治疗
CA2666814A1 (en) 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008068548A1 (en) 2006-12-08 2008-06-12 Institut Necker Use of inhibitors of the glycosylation process for the prevention and treatment of genetic diseases
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
EP2400843B1 (en) 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
EP2410989A2 (en) 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
WO2010144759A1 (en) 2009-06-12 2010-12-16 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
CN102595895A (zh) 2009-09-04 2012-07-18 联合治疗公司 亚氨基糖以及治疗丝状病毒性疾病的方法
JP5575246B2 (ja) 2009-09-04 2014-08-20 ユナイテッド セラピューティクス コーポレイション ポックスウイルス感染の治療方法
EP2473482B1 (en) 2009-09-04 2014-03-05 United Therapeutics Corporation Methods of treating orthomyxoviral infections

Also Published As

Publication number Publication date
EP2398321A1 (en) 2011-12-28
US8450345B2 (en) 2013-05-28
US20170304333A1 (en) 2017-10-26
JP5940607B2 (ja) 2016-06-29
HK1165221A1 (zh) 2012-10-05
KR101755133B1 (ko) 2017-07-06
JP2016175937A (ja) 2016-10-06
US9943532B2 (en) 2018-04-17
CN106420740A (zh) 2017-02-22
JP2012518649A (ja) 2012-08-16
CN102655746A (zh) 2012-09-05
EP2398321B1 (en) 2015-11-25
JP2014237706A (ja) 2014-12-18
US20100222383A1 (en) 2010-09-02
CA2753195A1 (en) 2010-08-26
KR20120042716A (ko) 2012-05-03
KR20150038684A (ko) 2015-04-08
US20130237567A1 (en) 2013-09-12
US9579334B2 (en) 2017-02-28
ES2579628T3 (es) 2016-08-12
EP2398321A4 (en) 2012-01-04
WO2010096764A1 (en) 2010-08-26
US9044470B2 (en) 2015-06-02
CA2753195C (en) 2015-06-02
CN102655746B (zh) 2016-08-03
US20150224128A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
JP5940607B2 (ja) イミノ糖およびウイルス性疾患を治療する方法
JP5653438B2 (ja) オルトミクソウイルス感染の治療方法
JP5752689B2 (ja) フィロウイルス疾患を治療するイミノ糖および方法
CN102625801B (zh) 治疗痘病毒感染的方法
KR101787434B1 (ko) 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법
EP3046558A2 (en) Deoxynojirimycin derivatives and methods of their using
HK1165221B (en) Iminosugars and methods of treating viral diseases
HK1173723B (en) Methods of treatlng poxviral infections

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140226

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140226

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140815

R150 Certificate of patent or registration of utility model

Ref document number: 5600329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees